This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard C. Boorse, MD; Michael Rhodes, MD

Arch Surg. 1990;125(2):274-275.

Abstract
• Neuroleptic malignant syndrome is a little-known adverse reaction to neuroleptic administration characterized by hyperpyrexia, leukocytosis, creatine kinase elevations, muscular rigidity, autonomic dysfunction, and alterations in level of consciousness. Neuroleptic malignant syndrome has an associated 20% mortality but can be reversed when treated with neuroleptic discontinuation and administration of bromocriptine and dantrolene. Early diagnosis in the trauma unit may prevent an extensive workup for presumed sepsis. To our knowledge, neuroleptic malignant syndrome has not previously been reported in a multiple trauma patient.

(Arch Surg. 1990;125:274-275)

Author Affiliations
From the Division of Trauma, Lehigh Valley Hospital Center, Allentown, Pa.

Footnotes
Accepted for publication August 12, 1989.

Reprint requests to Lehigh Valley Hospital Center, 1210 S Cedar Crest Blvd, Allentown, PA 18103 (Dr Rhodes).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroleptic Malignant Syndrome Complicating Antipsychotic Treatment of Delirium or Agitation in Medical and Surgical Patients: Case Reports and A Review of the Literature
Seitz and Gill
Psychosomatics 2009;50:8-15.
ABSTRACT | FULL TEXT